{
    "Clinical Trial ID": "NCT00030823",
    "Intervention": [
        "INTERVENTION 1: ",
        "  Vaccine",
        "  Patients receive Globo-H-GM2-Lewis-y-MUC1-32(aa)-sTn(c)-TF(c)-Tn(c)-KLH conjugate vaccine with QS21 adjuvant subcutaneously weekly on weeks 1, 2, 3, 7, and 19."
    ],
    "Eligibility": [
        "DISEASE CHARACTERISTICS:",
        "  Diagnosis of breast cancer at high risk for recurrence, defined by one of the following:",
        "  Stage IV that is free of all known disease after eradication by surgery, radiotherapy, or chemotherapy",
        "  May or may not have elevated CA 15-3 or CEA levels",
        "  Stage I, II, or III previously treated with adjuvant chemotherapy and clinically free of identifiable disease, but have rising CA 15-3 or CEA levels",
        "  Rising CA 15-3 and CEA defined as a prior normal level increased on 2 consecutive occasions at least 2 weeks apart",
        "  For patients with a significant history of smoking who have a chronically elevated CEA (less than 15), CEA must be increased at least 1.5 times the uppermost chronic value on 2 consecutive occasions at least 2 weeks apart",
        "  Stage III and completed adjuvant therapy no more than 24 months ago",
        "  Recurrence in the ipsilateral axilla after lumpectomy and/or axillary dissection or modified radical mastectomy",
        "  Recurrence in the ipsilateral breast after lumpectomy and/or axillary dissection",
        "  Stage II with at least 4 positive axillary nodes and completed adjuvant therapy no more than 24 months ago",
        "  Stage IV that is stable on hormonal therapy",
        "  Hormone receptor status:",
        "  Not specified",
        "  PATIENT CHARACTERISTICS:",
        "  Age:",
        "  18 and over",
        "  Sex:",
        "  Male or female",
        "  Menopausal status:",
        "  Not specified",
        "Performance status:",
        "  Karnofsky 80-100%",
        "  Life expectancy:",
        "  Not specified",
        "  Hematopoietic:",
        "  Lymphocyte count at least 500/mm^3",
        "  WBC at least 3,000/mm^3",
        "  Hepatic:",
        "  AST no greater than 1.5 times upper limit of normal (ULN)",
        "  Alkaline phosphatase no greater than 1.5 times ULN",
        "  Renal:",
        "  Creatinine no greater than 1.5 times ULN",
        "  Cardiovascular:",
        "  No clinically significant New York Heart Association class III or IV cardiac disease",
        "  Other:",
        "  Not pregnant",
        "  Negative pregnancy test",
        "  Fertile patients must use effective contraception",
        "  No prior seafood allergy",
        "  No known prior immunodeficiency or autoimmune disease",
        "  No other active cancer except basal cell or squamous cell skin cancer",
        "  PRIOR CONCURRENT THERAPY:",
        "  Biologic therapy:",
        "  At least 6 weeks since prior immunotherapy",
        "  No prior vaccine with any of the antigens in this study",
        "  Chemotherapy:",
        "  See Disease Characteristics",
        "  At least 4 weeks since prior chemotherapy",
        "  No concurrent chemotherapy",
        "  Endocrine therapy:",
        "  See Disease Characteristics",
        "  Radiotherapy:",
        "  See Disease Characteristics",
        "  At least 4 weeks since prior radiotherapy",
        "  No concurrent radiotherapy",
        "  Surgery:",
        "  See Disease Characteristics",
        "  At least 4 weeks since prior surgery",
        "  Concurrent surgery for local recurrence allowed if patient remains disease free"
    ],
    "Results": [
        "Outcome Measurement: ",
        "  Safety",
        "  By assessing the toxicity and will be graded following immunization with polyvalent vaccine in accordance with the NCI Common Toxicity Criteria 2.0.",
        "  Time frame: 2 years",
        "Results 1: ",
        "  Arm/Group Title: Vaccine",
        "  Arm/Group Description: Patients receive Globo-H-GM2-Lewis-y-MUC1-32(aa)-sTn(c)-TF(c)-Tn(c)-KLH conjugate vaccine with QS21 adjuvant subcutaneously weekly on weeks 1, 2, 3, 7, and 19.",
        "  Overall Number of Participants Analyzed: 13",
        "  Measure Type: Number",
        "  Unit of Measure: participants  13"
    ],
    "Adverse Events": [
        "Adverse Events 1:",
        "  Total: 1/13 (7.69%)",
        "  SGPT (ALT) 1/13 (7.69%)"
    ]
}